Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
Icofungipen (formerly PLD-118) is a synthetic derivative of the naturally occurring beta-amino acid cispentacin that blocks isoleucyl-tRNA synthetase, resulting in the inhibition of protein synthesis and growth of fungal cells. We investigated the efficacy, plasma pharmacokinetics, and safety of icofungipen in escalating dosages for the treatment of experimental subacute disseminated candidiasis in persistently neutropenic rabbits. Icofungipen was administered for 10 days starting 24 h after the intravenous inoculation of 10(3) Candida albicans blastoconidia. Study groups consisted of rabbits treated with icofungipen at 4 (ICO-4), 10 (ICO-10), and 25 (ICO-25) mg/kg of body weight/day in two divided dosages, rabbits treated with fluconazole at 10 mg/kg/day, rabbits treated with amphotericin B at 1 mg/kg/day, and untreated controls. Levels of icofungipen in plasma were derivatized by phthaldialdehyde and quantified by high-performance liquid chromatography with fluorescence detection. Rabbits treated with ICO-10 (P < 0.01) and ICO-25 (P < 0.001) showed significant dosage-dependent tissue clearance of C. albicans from the liver, spleen, kidney, brain, vitreous, vena cava, and lung in comparison to untreated controls. ICO-25 cleared C. albicans from all tissues and had activity comparable to that of amphotericin B versus untreated controls (P < 0.001). Pharmacokinetics of icofungipen in plasma approximated a dose-dependent relationship of the maximum concentration of drug in serum and the area under the concentration-time curve. There was no significant elevation of the levels of hepatic transaminases, alkaline phosphatase, bilirubin, urea nitrogen, or creatinine in icofungipen-treated rabbits. Icofungipen followed dose-dependent pharmacokinetics and was effective in the treatment of experimental disseminated candidiasis, including central nervous system infection, in persistently neutropenic rabbits.
Petraitiene
Ruta
R
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892-1100, USA.
Petraitis
Vidmantas
V
Kelaher
Amy M
AM
Sarafandi
Alia A
AA
Mickiene
Diana
D
Groll
Andreas H
AH
Sein
Tin
T
Bacher
John
J
Walsh
Thomas J
TJ
D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D003470:Culture Media; D003515:Cycloleucine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D007165:Immunosuppression Therapy; D007533:Isoleucine-tRNA Ligase / Q000037:antagonists & inhibitors*; D007668:Kidney / Q000382:microbiology; D008099:Liver / Q000382:microbiology; D009503:Neutropenia / Q000150:complications*; D011817:Rabbits; D013154:Spleen / Q000382:microbiology
D000935:Antifungal Agents; D003470:Culture Media; D003515:Cycloleucine; D007533:Isoleucine-tRNA Ligase; C114614:2-amino-4-methylenecyclopentane-1-carboxylic acid